Health charities and pharmaceutical money: partnership or compromise?

The debate in brief

Pharmaceutical companies fund patient charities. This is not a secret, but the scale and implications are poorly understood. Industry sponsorship flows to health charities through educational grants, project funding, sponsorship of events and conferences, joint campaigns, and unrestricted donations. The Association of the British Pharmaceutical Industry (ABPI) requires its members to disclose payments to patient organisations, and many charities publish their pharmaceutical funding. But transparency is uneven, and the underlying question remains: can a charity campaign for access to a drug while accepting money from the company that manufactures it?

The answer matters because patient charities are among the most trusted voices in health policy. When a cancer charity calls for NICE to approve a new treatment, or a rare disease charity advocates for a drug to be added to the NHS formulary, their credibility rests on their independence. If that independence is compromised -- or perceived to be compromised -- by financial relationships with the manufacturers of those drugs, the entire model of patient advocacy is undermined.

Quick takeaways

The arguments

The case that pharmaceutical funding compromises independence

The concern is not that patient charities are corrupt. It is that financial relationships with pharmaceutical companies create structural incentives that are difficult to manage, even with good governance. A charity that receives significant funding from a company manufacturing a cancer drug has a financial interest in maintaining that relationship. If the charity then campaigns for NHS access to that drug, the campaign may be entirely genuine -- the drug may be clinically effective and patient access may be a legitimate cause. But the financial relationship creates a reasonable perception that the campaign is influenced by the sponsor rather than driven solely by patient need.

Research published in the BMJ and by the King's Fund has documented cases where patient charities' public positions on drug access aligned closely with their pharmaceutical sponsors' commercial interests. A 2022 BMJ investigation examined the funding relationships between pharmaceutical companies and patient organisations that had submitted evidence to NICE technology appraisals, finding that a significant proportion of patient organisations contributing evidence in favour of drug approval received funding from the manufacturer of the drug in question. The organisations' evidence was not necessarily wrong -- patient testimony is a legitimate input to NICE appraisals -- but the financial relationship was frequently undisclosed in the appraisal submissions.

The dynamic is particularly acute in rare diseases. Rare disease patient organisations are often very small, with limited income and no fundraising infrastructure. A pharmaceutical company developing a treatment for a rare condition may be the only significant funder available to the patient organisation. This creates a dependency in which the charity's survival is linked to its relationship with a single company -- a relationship that is extremely difficult to manage at arm's length.

The case that pharmaceutical partnerships serve patients

The counter-argument is pragmatic. Patient charities need funding. The state does not provide it. Individual donors give generously to high-profile conditions but far less to the smaller, less visible charities that represent patients with rarer or more stigmatised conditions. Pharmaceutical companies offer funding that enables charities to provide patient support services, educational materials, helplines, and advocacy that would not otherwise exist.

The relationship is also not one-directional. Patient charities bring pharmaceutical companies something they cannot easily obtain elsewhere: the trust and engagement of patient communities. When a pharmaceutical company wants to understand the patient experience of a disease, recruit for clinical trials, or design patient-reported outcomes measures, patient charities are essential partners. This collaboration can produce better drugs, better trial design, and better outcomes for patients.

Defenders of the partnership model point to governance mechanisms that manage conflicts of interest. Many charities have policies requiring that pharmaceutical funding does not influence their editorial or campaigning positions. The ABPI Code requires transparency about payments. The Charity Commission's CC29 guidance sets out trustees' duties to identify and manage conflicts. The argument is not that conflicts do not exist but that they can be managed through good governance, transparency, and clear organisational boundaries.

The transparency gap

The most productive area of the debate concerns not whether pharmaceutical funding should exist but whether it is sufficiently transparent. Current disclosure requirements are fragmented. The ABPI requires its members to disclose payments to patient organisations, but not all pharmaceutical companies operating in the UK are ABPI members. Charities disclose major income sources in their annual accounts but are not required to identify pharmaceutical funding separately. A member of the public attempting to understand the financial relationship between a patient charity and a pharmaceutical company would need to cross-reference the ABPI disclosure database with individual charity accounts -- a task that is technically possible but practically difficult.

Several health charities have adopted stronger voluntary disclosure standards, publishing detailed lists of their pharmaceutical funders and the amounts received. Cancer Research UK, for example, publishes its pharmaceutical partnerships prominently. But many smaller charities disclose less, and some disclose nothing beyond the minimum required by accounting standards. The result is a transparency landscape that is patchy enough to sustain suspicion without providing the information needed to assess whether conflicts of interest are being properly managed.

The evidence

The BMJ has published several investigations into pharmaceutical industry funding of patient organisations in the UK. A 2022 analysis examined the funding relationships behind evidence submissions to NICE technology appraisals, finding that a significant number of patient organisations submitting evidence had financial relationships with the manufacturer of the drug under review, and that these relationships were frequently undisclosed in the submission. The research was led by academics at the University of Bath and the University of York.

The ABPI publishes an annual aggregate disclosure of payments to patient organisations by its member companies. The most recent data shows payments totalling tens of millions of pounds annually, distributed across hundreds of UK patient organisations. Individual company disclosures are also available through the ABPI's Disclosure UK database, though navigating this data requires significant effort.

The Charity Commission's CC29 guidance sets out the legal framework for managing conflicts of interest in charities, including conflicts arising from commercial relationships with funders. The guidance is general rather than specific to pharmaceutical funding and does not impose sector-specific requirements on health charities.

Research by academics at the University of York, published in Health Policy, has examined the influence of pharmaceutical industry funding on patient organisations' positions on health technology assessment, finding correlations between funding and advocacy positions while noting the difficulty of establishing causation. A 2019 study in PLOS ONE examined pharmaceutical industry funding of patient organisations across Europe, finding that the UK had among the highest levels of industry-to-patient-organisation financial flows.

The Patients Association and National Voices, both umbrella bodies for patient organisations, have published guidance on managing pharmaceutical relationships, emphasising the importance of written agreements, editorial independence, and public disclosure.

Current context

The debate has gained renewed attention following high-profile drug access campaigns in which patient charities played a central role. The campaign to secure NHS access to Kaftrio (elexacaftor/tezacaftor/ivacaftor) for cystic fibrosis patients, led in part by the Cystic Fibrosis Trust, involved sustained public advocacy while the Trust had a disclosed financial relationship with Vertex Pharmaceuticals, the drug's manufacturer. The drug was approved by NICE and is now available on the NHS. The campaign was widely viewed as a patient-led success, but it also illustrated the difficulty of separating patient advocacy from manufacturer interest when both parties want the same outcome -- NHS approval of the drug.

The Prescription Medicines Code of Practice Authority (PMCPA), which administers the ABPI Code, has continued to investigate complaints about pharmaceutical company relationships with patient organisations. Cases have included allegations of undisclosed payments, inappropriate influence over patient organisation materials, and failures to ensure editorial independence.

In 2025, NHS England published updated guidance on managing conflicts of interest in health decision-making, including specific reference to pharmaceutical industry relationships with patient organisations that contribute evidence to commissioning decisions. The guidance stops short of requiring patient organisations to disclose pharmaceutical funding when submitting evidence but recommends it as good practice.

The broader political context is relevant. The UK government's life sciences strategy emphasises partnership between the NHS, industry, and the charitable sector as essential to attracting pharmaceutical investment and accelerating patient access to innovative treatments. This policy framework positions pharmaceutical-charity relationships as desirable rather than problematic, creating tension with the governance concerns raised by researchers and transparency advocates.

Last updated: April 2026

What this means for charities

Health charities that accept pharmaceutical funding face a permanent governance challenge. The funding may be essential, the partnership may be genuine, and the resulting services may benefit patients. But the conflict of interest is structural, not incidental, and it requires active management rather than assurance that "we would never let funding influence our positions."

Practical steps for charities include publishing comprehensive lists of pharmaceutical funders and amounts, maintaining written agreements that guarantee editorial and campaigning independence, ensuring that trustees with pharmaceutical industry connections declare their interests and recuse themselves from relevant decisions, and subjecting drug access campaigns to internal review processes that specifically assess whether the campaign position aligns with the interests of a pharmaceutical funder.

For the wider sector, the pharmaceutical funding debate raises a question that applies across all areas of charitable activity: at what point does a funder relationship become so significant that it compromises the charity's ability to act independently? The answer is not a percentage threshold or a financial figure. It is a governance question that trustees must answer honestly, case by case, with full awareness that the appearance of independence is as important as the reality.

Common questions

Is pharmaceutical funding of charities wrong?

Not inherently. Pharmaceutical companies have legitimate interests in supporting patient communities, and patient charities have legitimate funding needs. The issue is whether the relationships are transparent, whether conflicts of interest are managed effectively, and whether the charity retains genuine independence in its positions and campaigns. Well-governed pharmaceutical partnerships can serve patients. Poorly governed ones can serve industry.

Do pharmaceutical companies fund charities to influence NICE decisions?

This is the central allegation, and it is difficult to prove or disprove. NICE technology appraisals consider patient evidence alongside clinical and economic evidence. Patient organisations that submit evidence in favour of drug approval may do so entirely on the basis of patient need, even when they receive funding from the manufacturer. But the pattern -- manufacturer funds patient organisation, patient organisation submits evidence supporting approval of manufacturer's drug -- is sufficiently consistent to raise legitimate questions about structural influence even in the absence of direct pressure.

What do the rules require?

Charity law requires trustees to manage conflicts of interest (CC29). Accounting standards (SORP) require disclosure of major income sources. The ABPI Code requires pharmaceutical companies to disclose payments to patient organisations. But there is no specific regulatory requirement for health charities to disclose pharmaceutical funding separately from other income, and no requirement to disclose pharmaceutical relationships when submitting evidence to NICE or other bodies. The regulatory framework relies on general duties rather than sector-specific rules.

How do rare disease charities manage these relationships?

With great difficulty. A rare disease charity may have only one pharmaceutical company operating in its disease area, making the relationship impossible to diversify. The dependency is stark: the company's funding may constitute a majority of the charity's income. Good governance requires clear written agreements, editorial firewalls, and honest communication with patients about the funding relationship. Some rare disease charities have managed these relationships well. Others have found it impossible to maintain meaningful independence from their sole significant funder.

Should NICE require disclosure of pharmaceutical funding?

Many researchers and transparency advocates believe so. Currently, patient organisations submitting evidence to NICE technology appraisals are asked but not required to disclose pharmaceutical funding relationships. The NHS England 2025 guidance recommends disclosure as good practice but does not mandate it. Mandatory disclosure would not prevent pharmaceutical-funded charities from submitting evidence but would allow NICE committees to assess the evidence with full knowledge of the funding context.

What can donors do?

Donors can check whether charities they support disclose their pharmaceutical funding relationships. Charity accounts, ABPI disclosures, and organisational websites provide varying levels of information. Donors who are concerned about pharmaceutical influence can prioritise charities with strong transparency policies and clear governance frameworks for managing commercial relationships. Donors can also ask charities directly about their pharmaceutical funding -- organisations that are managing these relationships well should be willing to discuss them openly.

Key sources and further reading

• BMJ Investigations into Pharmaceutical Funding of Patient Organisations -- BMJ, 2022 and ongoing. Investigative reporting and academic research on the financial relationships between pharmaceutical companies and UK patient organisations.

• ABPI Code of Practice and Disclosure UK Database -- Association of the British Pharmaceutical Industry. The industry code governing interactions with patient organisations, and the public database of disclosed payments.

• CC29: Conflicts of Interest -- A Guide for Charity Trustees -- Charity Commission for England and Wales. The regulatory guidance setting out trustees' duties to identify and manage conflicts of interest.

• "Pharmaceutical Industry Funding of Patient Organisations in the UK" -- Health Policy, University of York. Academic research examining the extent and influence of pharmaceutical funding on patient advocacy.

• NICE Patient and Public Involvement Policy -- National Institute for Health and Care Excellence. NICE's framework for incorporating patient evidence into technology appraisals, including guidance on disclosure of interests.

• NHS England Guidance on Managing Conflicts of Interest -- NHS England, 2025. Updated guidance on conflicts of interest in health commissioning and decision-making, with specific reference to pharmaceutical industry relationships.

• Patients Association Guidance on Industry Relationships -- Patients Association. Practical guidance for patient organisations on managing pharmaceutical company partnerships while maintaining independence.

• "Pharmaceutical Company Payments to Patient Organisations across Europe" -- PLOS ONE, 2019. Comparative analysis of industry-to-patient-organisation financial flows across European countries.